StemRIM Inc. (JP:4599)
:4599
Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥360.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥18.74B
Enterprise Value¥14.29B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.42
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageNear-zero debt materially lowers financial risk and preserves strategic optionality. Over the next several months management can prioritize R&D, partnerships, or selective financings without large interest burdens, providing durable flexibility while the firm attempts to rebuild revenue.
Licensing-based Revenue ModelA licensing and collaboration model shifts capital intensity away from direct commercialization and lets partners fund late-stage development. This structure can scale revenue via milestone and royalty streams if technologies gain adoption, reducing long-term capital requirements vs full commercialization.
Regenerative Medicine FocusConcentration on regenerative and stem-cell therapies positions the company in a structural, high-value segment of biotech with persistent R&D demand. Proprietary technology focus supports differentiated programs and the potential for durable partnership interest from larger pharma seeking novel assets.
Bears Say
Revenue CollapseComplete disappearance of reported revenue shows no sustained commercial traction or recurring licensing receipts, undermining the company's ability to fund operations internally. This structural revenue void increases execution risk and weakens bargaining leverage with partners over months to years.
Large, Persistent Cash BurnSustained negative operating cash flow signals ongoing funding shortfalls and a reliance on balance sheet resources or external capital. Persistent burn constrains R&D pacing and raises the likelihood of dilutive financings or curtailed programs, impairing long-term growth prospects without corrective measures.
Eroding Equity CushionDeclining shareholders' equity reflects cumulative losses that are shrinking the company's capital buffer. A thinner equity base reduces resilience to future setbacks, limits borrowing capacity despite low debt, and increases the probability of capital raises that dilute existing holders and stress long-term program funding.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥360.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥18.74B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Jun 17, 2026 which is in 44 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Mar 11, 2026. The company reported -¥6.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.42.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥6.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.333%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---